April 3, 2014
1:00 pm to 2:00 pm EDT
Sponsored by
Webinar Description:
Andreas Jeromin, PhD, will provide an overview of the existing protein-based biomarkers in (mild) traumatic brain injury and will discuss their potential application in the clinical management of mild traumatic brain injury. While the majority of brain-enriched or specific biomarkers of neuronal injury have been assessed in cerebrospinal fluid (CSF), their low abundance in blood has a major hurdle in their reliable detection. Dr. Jeromin will describe the use of Simoa technology developed by Quanterix in detecting total tau in blood in sports-related concussion. The Simoa technology provides broad research and clinical applications in neurology and neurodegeneration.
Learning Objectives:
To understand:
a.) the definition of TBI
b.) unmet medical need in TBI
c.) current status of biomarker discovery and verification
d.) clinical utility of biomarker tests in TBI - emergency department vs. point-of-care
e.) technology/platform landscape
Speaker Information
Dr. David Wilson, PhD
Vice President of Product Development
Quanterix Corporation
Dr. Wilson joined Quanterix in 2010 to lead the development of breakthrough diagnostic products using single molecule detection technology. Dr. Wilson brings 20 years of leadership experience in in-vitro diagnostics product development at Abbott Laboratories where he developed and commercialized over 20 new products across the major clinical diagnostic areas. His technical accomplishments include a groundbreaking product for hemoglobin A1c monitoring using novel capture and detection technologies (U.S. patent and $80MM in revenue). He also has extensive partnership experience including leading a successful companion diagnostic venture with Wyeth. Most recently, Dr. Wilson pioneered an entrepreneurial accelerated product development model partnering with smaller diagnostics firms that cut time-to-market by half and cost by two-thirds. He is lead author of over 25 articles and abstracts, inventor on two U.S. patents, and recipient of numerous awards, including three Chairman Awards and four Entrepreneurial Awards. Dr. Wilson received his Ph.D. in biophysical chemistry and his M.S. in chemistry from the University of Illinois/Chicago. He obtained his B.A. in chemistry from the University of South Florida.
Dr. Andreas Jeromin, PhD
Scientific and Medical Advisor
Quanterix Corporation
Andreas Jeromin, PhD, has established research programs in translational neuroscience in both industry and biotech for the last 15 years and co-authored more than 100 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas Jeromin has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration. This included several drug development programs from POC to a NINDS-supported phase III trial (Protect III). He also supports as member of the SABs or steering committee, several biomarker qualification efforts such as ADNI, the Coalition against Major Diseases (CAMD) directed by the Critical Path Institute (C-PATH), the Alzheimer's Association CSF QC and biomarker assay standardization initiatives in other CNS disorders, including MS (Accelerated Cure, ALS and PD. He is the founder and CSO of Atlantic Biomarkers, LLC, and joined Quanterix, Inc. as scientific and medical advisor in 2014.
Cost: No cost!